Pharmaron Ocular Testing Services for Drug Permeability and Formulation

🔬 Decoding protein glycation chemistry enables design of anti‑AGE therapeutics and diagnostics. ✨ Consider how mastering protein glycation chemistry empowers you to create anti-AGE drugs, protective traps, and real-time imaging tools. Integrating this biological insight bridges organic synthesis and therapeutic design, accelerating development of interventions that halt disease pathways and enable precise diagnostic monitoring. ✓ 🔬Maps lysine-arginine crosslinking mechanisms to create small molecules that intercept early glycation intermediates, preventing diabetic complications. ✓ 🛡️Designs reversible dicarbonyl traps mimicking serum albumin's protective role, reducing AGE accumulation in long-lived proteins. ✓ 💡Exploits AGE-binding pocket chemistry to deliver fluorescence probes that visualize tissue glycation in real-time, aiding early diagnosis. 🟢 How has incorporating glycation biology reshaped your approach to designing organic molecules? #OrganicChemistry #Glycation #DrugDesign #Diagnostics #Interdisciplinary

🔬 Decoding protein glycation chemistry enables design of anti‑AGE therapeutics and diagnostics. ✨ Consider how mastering protein glycation chemistry empowers you to create anti-AGE drugs, protective traps, and real-time imaging tools. Integrating this biological insight bridges organic synthesis and therapeutic design, accelerating development of interventions that halt disease pathways and enable precise diagnostic monitoring. ✓ 🔬Maps lysine-arginine crosslinking mechanisms to create small molecules that intercept early glycation intermediates, preventing diabetic complications. ✓ 🛡️Designs reversible dicarbonyl traps mimicking serum albumin's protective role, reducing AGE accumulation in long-lived proteins. ✓ 💡Exploits AGE-binding pocket chemistry to deliver fluorescence probes that visualize tissue glycation in real-time, aiding early diagnosis. 🟢 How has incorporating glycation biology reshaped your approach to designing organic molecules? #OrganicChemistry #Glycation #DrugDesign #Diagnostics #Interdisciplinary

🔬 Decoding protein glycation chemistry enables design of anti‑AGE therapeutics and diagnostics. ✨ Consider how mastering protein glycation chemistry empowers you to create anti-AGE drugs, protective traps, and real-time imaging tools. Integrating this biological insight bridges organic synthesis and therapeutic design, accelerating development of interventions that halt disease pathways and enable precise diagnostic monitoring. ✓ 🔬Maps lysine-arginine crosslinking mechanisms to create small molecules that intercept early glycation intermediates, preventing diabetic complications. ✓ 🛡️Designs reversible dicarbonyl traps mimicking serum albumin's protective role, reducing AGE accumulation in long-lived proteins. ✓ 💡Exploits AGE-binding pocket chemistry to deliver fluorescence probes that visualize tissue glycation in real-time, aiding early diagnosis. 🟢 How has incorporating glycation biology reshaped your approach to designing organic molecules? #OrganicChemistry #Glycation #DrugDesign #Diagnostics #Interdisciplinary

Stop struggling with scarce clinical samples. Our latest poster introduces a surrogate blister fluid matrix approach, a smarter alternative for flow cytometry assay validation. This innovative method enables fit-for-purpose validation in regulated bioanalysis, bypassing the hurdle of limited sample access without compromising data integrity. What you’ll learn: • A Proven Surrogate Matrix: A practical, reproducible solution to overcome clinical sample scarcity. • Enhanced Assay Validation: Precision-engineered consistency for high-stakes flow cytometry. • Robust Bioanalytical Data: How to strengthen drug development programs with reliable, scalable validation strategies. Explore the scientific findings with Martin Turcotte, our Scientific Director of Flow Cytometry: https://lnkd.in/giFdrDTQ #Bioanalysis #FlowCytometry #AssayValidation

The "Sniper" approach to wound care: Faster, more precise, and antibiotic-free. A few weeks ago, we shared how our MTC-Y technology acts like a „sniper" - delivering active substances exactly where they are needed, bypassing the body's natural barriers. Today, we have the peer-reviewed data to prove it. Our latest study in Frontiers in Pharmacology confirms that this precision-delivery approach is no longer just a theory. Results from our translational model are clear: ✅ 29% Faster Healing: significantly outperforming standard antibiotic treatment. ✅ Reduced Recovery Time: saving nearly 4 days in the healing process of infected, necrotic wounds. ✅ Antibiotic-Sparing: effectively managing inflammation and biofilm without contributing to the global AMR crisis. This milestone validates the potential of our technology to transform how we treat chronic wounds. We’ve proven that we can take challenging compounds from our pipeline and turn them into validated therapies that meet rigorous performance benchmarks. Read the full peer-reviewed study: [ link in the first comment ] #Biotts #DrugDelivery #WoundCare #PharmaInnovation #AMR #Biotech #LifeSciences #Transdermal

𝗟𝗼𝗼𝗸𝗶𝗻𝗴 𝗳𝗼𝗿𝘄𝗮𝗿𝗱 𝘁𝗼 𝘀𝗽𝗲𝗮𝗸𝗶𝗻𝗴 𝗮𝘁 𝘁𝗵𝗲 𝟯𝗿𝗱 𝗔𝗻𝗻𝘂𝗮𝗹 𝗣𝗲𝗽𝘁𝗶𝗱𝗲-𝗕𝗮𝘀𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗦𝘂𝗺𝗺𝗶𝘁 (𝗔𝗽𝗿𝗶𝗹 𝟮𝟴-𝟯𝟬, 𝗕𝗼𝘀𝘁𝗼𝗻, 𝗠𝗔). I’ll be presenting at the pre-conference workshop this Tuesday, April 28 at 10:00 (Workshop A – Artificial Intelligence for Peptide Design): 𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁 𝗖𝗮𝘀𝗲 𝗦𝘁𝘂𝗱𝘆 𝟯: 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 & 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗶𝗻 𝗢𝗿𝗮𝗹 𝗣𝗲𝗽𝘁𝗶𝗱𝗲 𝗗𝗲𝘀𝗶𝗴𝗻 & 𝗙𝗼𝗿𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 Peptide drug discovery has long been limited by scarce native ligands and slow optimization. AI/ML is beginning to shift this – enabling faster design, activity prediction, and candidate optimization. At the same time, oral delivery remains a major hurdle, requiring careful balance between stability, permeability, bioavailability, and target engagement. In this session, I’ll share Pepticom Ltd.’s approach and experience in applying AI-driven design to address these challenges earlier in the discovery process – and where key bottlenecks still remain. If you’re attending, please stop by the session. Looking forward to the discussions with a great group of experts in the field - Joshua Schwochert, Ajay Kshatriya and others shaping the future of peptide therapeutics. #PeptideTherapeutics #DrugDiscovery #AI #OralPeptides #Biotech Tomi Sawyer

🎯 A well-designed imaging study generates a complete PK dataset from a single cohort. A poorly designed one wastes animals, budget, and months — while answering the wrong question. The most common mistake in preclinical molecular imaging? Treating it as a "take a picture and see what happens" exercise. In reality, every parameter — from isotope selection to imaging timepoints — must align precisely with your development objective. Here's what separates publication-ready imaging data from expensive noise: Step 1: Crystallize the scientific question before touching an isotope. Are you measuring biodistribution? Target engagement? Dose optimization? Each demands a fundamentally different protocol. Step 2: Match your radiolabeling strategy to the question. Isotope half-life must match drug kinetics, chelator stability must be proven for your drug class, and QC methods must be established — all before animal model selection. Step 3: Choose imaging timepoints strategically. For Zr-89-labeled antibodies, you need 4h through 168h coverage. For Ga-68 peptides, dynamic imaging over 60-90 minutes. Miss the right window, and your PK profile has holes that no post-hoc analysis can fill. Step 4: Standardize acquisition and reconstruction. Scanner-isotope combinations need validated parameters benchmarked against known activity phantoms. The payoff? A single well-designed study can replace multiple poorly planned ones — saving 3-6 months and significant budget while generating regulatory-grade data. At molim, study design consultation is the first step in every engagement. Not because it's a formality — because it's where the majority of a study's value is created. 𝘚𝘰𝘶𝘳𝘤𝘦: 𝘮𝘰𝘭𝘪𝘮 𝘞𝘦𝘦𝘬𝘭𝘺 𝘚𝘦𝘳𝘪𝘦𝘴 — 𝘔𝘰𝘭𝘦𝘤𝘶𝘭𝘢𝘳 𝘐𝘮𝘢𝘨𝘪𝘯𝘨 & 𝘋𝘳𝘶𝘨 𝘋𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘌𝘱𝘪𝘴𝘰𝘥𝘦 11 📖 Read full article: Designing an Imaging Study — From Protocol to Publication-Ready Data - https://lnkd.in/gXUaZCy8 - #MolecularImaging #PreclinicalImaging #StudyDesign #DrugDevelopment #PETImaging #Radiopharmaceuticals #Biodistribution #Pharmacokinetics #NuclearMedicine #ImagingCRO #molimInc #PreclinicalCRO

🎯 A well-designed imaging study generates a complete PK dataset from a single cohort. A poorly designed one wastes animals, budget, and months — while answering the wrong question. The most common mistake in preclinical molecular imaging? Treating it as a "take a picture and see what happens" exercise. In reality, every parameter — from isotope selection to imaging timepoints — must align precisely with your development objective. Here's what separates publication-ready imaging data from expensive noise: Step 1: Crystallize the scientific question before touching an isotope. Are you measuring biodistribution? Target engagement? Dose optimization? Each demands a fundamentally different protocol. Step 2: Match your radiolabeling strategy to the question. Isotope half-life must match drug kinetics, chelator stability must be proven for your drug class, and QC methods must be established — all before animal model selection. Step 3: Choose imaging timepoints strategically. For Zr-89-labeled antibodies, you need 4h through 168h coverage. For Ga-68 peptides, dynamic imaging over 60-90 minutes. Miss the right window, and your PK profile has holes that no post-hoc analysis can fill. Step 4: Standardize acquisition and reconstruction. Scanner-isotope combinations need validated parameters benchmarked against known activity phantoms. The payoff? A single well-designed study can replace multiple poorly planned ones — saving 3-6 months and significant budget while generating regulatory-grade data. At molim, study design consultation is the first step in every engagement. Not because it's a formality — because it's where the majority of a study's value is created. 𝘚𝘰𝘶𝘳𝘤𝘦: 𝘮𝘰𝘭𝘪𝘮 𝘞𝘦𝘦𝘬𝘭𝘺 𝘚𝘦𝘳𝘪𝘦𝘴 — 𝘔𝘰𝘭𝘦𝘤𝘶𝘭𝘢𝘳 𝘐𝘮𝘢𝘨𝘪𝘯𝘨 & 𝘋𝘳𝘶𝘨 𝘋𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘌𝘱𝘪𝘴𝘰𝘥𝘦 11 📖 Read full article: Designing an Imaging Study — From Protocol to Publication-Ready Data - https://lnkd.in/g_CUjzKS - #MolecularImaging #PreclinicalImaging #StudyDesign #DrugDevelopment #PETImaging #Radiopharmaceuticals #Biodistribution #Pharmacokinetics #NuclearMedicine #ImagingCRO #molimInc #PreclinicalCRO

Serum has been a necessary compromise in T cell culture for years. But it comes with tradeoffs: variability, risk, and regulatory complexity. As more cell therapies move toward commercialization, those tradeoffs are getting harder to justify. So we asked a simple question: Can you remove serum without sacrificing performance? The answer is yes. Check out our white paper where we compare Physiologix performance to human serum as a supplement for T cell growth, expansion, and viability. We saw: ☑️Equivalent growth and viability ☑️Maintained functional markers ☑️Enhanced transduction efficiency That last one is impactful. 💥 Higher transduction efficiency = greater proportion of transfected cells and, in turn, a higher potency final product at lower manufacturing costs. If you're working with T cells, this is worth a closer look. 📄 Download the full white paper here: https://lnkd.in/gPthFep5 #SerumReplacement #Serum #CellTherapy #CART #Bioprocessing #CellCulture #CGT #Biotech #CellCultureMedia

Since many of my connections are working on AOCs, I am sharing this recently published review paper from UTHealth Houston. It is a great one-stop resource covering everything from antibody selection, oligonucleotide payload types, conjugation strategies (covalent vs. non-covalent, stochastic vs. site-specific), and linker chemistry, to AOC pharmacokinetics, intracellular trafficking, endosomal escape challenges, and the latest clinical pipeline highlights from Avidity, Dyne, Tallac, and Denali. If you're working on AOC development, analytics, or delivery, I highly recommend giving it a read! 💊🧬 https://lnkd.in/g3gFFbY7 #AOC #AntibodyOligonucleotideConjugate #RNATherapeutics #Biotherapeutics #DrugDelivery #ADC